PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 31757863-4 2019 We also found that BLM administration induced the release of the danger-associated molecular pattern HMGB-1, which caused CD300c2-deficient alveolar macrophages, via TLR4, to produce lower levels of neutrophil chemoattractants than wild-type alveolar macrophages. Bleomycin 19-22 toll-like receptor 4 Mus musculus 166-170 33290968-0 2021 Pinocembrin relieves lipopolysaccharide and bleomycin induced lung inflammation via inhibiting TLR4-NF-kappaB-NLRP3 inflammasome signaling pathway. Bleomycin 44-53 toll-like receptor 4 Mus musculus 95-99 25302613-4 2015 METHODS: We generated a murine model of bleomycin-induced SSc using TLR-4(-/-) mice and TLR-4(-/-) ;TSK/+ mice. Bleomycin 40-49 toll-like receptor 4 Mus musculus 68-73 26782380-0 2015 Toll-like receptor 4 promotes fibrosis in bleomycin-induced lung injury in mice. Bleomycin 42-51 toll-like receptor 4 Mus musculus 0-20 26782380-1 2015 The specific role of Toll-like receptor 4 (TLR4) in bleomycin-induced lung fibrosis of mice, a model of human idiopathic pulmonary fibrosis, has not been characterized. Bleomycin 52-61 toll-like receptor 4 Mus musculus 21-41 26782380-1 2015 The specific role of Toll-like receptor 4 (TLR4) in bleomycin-induced lung fibrosis of mice, a model of human idiopathic pulmonary fibrosis, has not been characterized. Bleomycin 52-61 toll-like receptor 4 Mus musculus 43-47 26782380-7 2015 Hydroxyproline content was significantly lower in TLR4(-/-) than in WT mice on day 21 after bleomycin injection (0.281 +- 0.022 vs 0.371 +- 0.047, P < 0.05). Bleomycin 92-101 toll-like receptor 4 Mus musculus 50-54 26782380-8 2015 Compared to WT mice, bleomycin-treated TLR4(-/-) mice expressed significantly lower type I collagen mRNA levels (mesenchymal marker; 11.069 +- 2.627 vs 4.589 +- 1.440, P < 0.05). Bleomycin 21-30 toll-like receptor 4 Mus musculus 39-43 26782380-10 2015 Bleomycin-treated TLR4(-/-) mice had a significantly lower mortality rate on day 21 than WT mice (33 vs 75%, P < 0.05). Bleomycin 0-9 toll-like receptor 4 Mus musculus 18-22 26782380-12 2015 Thus, bleomycin-induced pulmonary fibrosis is TLR4-dependent and TLR4 promoted fibrosis in bleomycin-challenged mice. Bleomycin 6-15 toll-like receptor 4 Mus musculus 46-50 26782380-12 2015 Thus, bleomycin-induced pulmonary fibrosis is TLR4-dependent and TLR4 promoted fibrosis in bleomycin-challenged mice. Bleomycin 6-15 toll-like receptor 4 Mus musculus 65-69 26782380-12 2015 Thus, bleomycin-induced pulmonary fibrosis is TLR4-dependent and TLR4 promoted fibrosis in bleomycin-challenged mice. Bleomycin 91-100 toll-like receptor 4 Mus musculus 65-69 25673924-10 2015 In bleomycin-induced SSc mouse models, endogenous ligands for toll-like receptor 4 induced by bleomycin stimulated B cells to produce various fibrogenic cytokines and autoantibodies. Bleomycin 3-12 toll-like receptor 4 Mus musculus 62-82 25673924-10 2015 In bleomycin-induced SSc mouse models, endogenous ligands for toll-like receptor 4 induced by bleomycin stimulated B cells to produce various fibrogenic cytokines and autoantibodies. Bleomycin 94-103 toll-like receptor 4 Mus musculus 62-82 30847938-0 2019 Mangiferin attenuates bleomycin-induced pulmonary fibrosis in mice through inhibiting TLR4/p65 and TGF-beta1/Smad2/3 pathway. Bleomycin 22-31 toll-like receptor 4 Mus musculus 86-90 25302613-6 2015 RESULTS: Dermal and lung fibrosis was attenuated in bleomycin-treated TLR-4(-/-) mice compared with their wild-type counterparts. Bleomycin 52-61 toll-like receptor 4 Mus musculus 70-75 25302613-7 2015 Inflammatory cell infiltration, expression of various inflammatory cytokines, and pathologic angiogenesis induced by bleomycin treatment were suppressed with TLR-4 deletion. Bleomycin 117-126 toll-like receptor 4 Mus musculus 158-163 25302613-8 2015 Furthermore, the increased expression of interleukin-6 (IL-6) in fibroblasts, endothelial cells, and immune cells in response to bleomycin in vivo and to lipopolysaccharide in vitro was notably abrogated in the absence of TLR-4. Bleomycin 129-138 toll-like receptor 4 Mus musculus 222-227 25302613-9 2015 Moreover, TLR-4 deletion was associated with alleviated B cell activation and skew toward a Th2/Th17 response against bleomycin treatment. Bleomycin 118-127 toll-like receptor 4 Mus musculus 10-15 18467694-7 2008 These results suggest that bleomycin induces fibrosis by enhancing hyaluronan production, which activates B cells to produce fibrogenic cytokines mainly via TLR4 and induce autoantibody production, and that CD19 deficiency suppresses fibrosis and autoantibody production by inhibiting TLR4 signals. Bleomycin 27-36 toll-like receptor 4 Mus musculus 157-161 23141927-5 2013 These profibrotic responses were abrogated by both genetic and pharmacological disruption of TLR4 signaling in vitro, and skin fibrosis induced by bleomycin in vivo was attenuated in mice harboring a mutated TLR4. Bleomycin 147-156 toll-like receptor 4 Mus musculus 208-212 22062220-3 2012 We found that genetic or pharmacologic inhibition of TLR4 exacerbates bleomycin-induced pulmonary inflammation, fibrosis, dysfunction, and animal death through promoting formation of an immunosuppressive tissue microenvironment and attenuating autophagy-associated degradation of collagen and cell death in the fibrotic lung tissues. Bleomycin 70-79 toll-like receptor 4 Mus musculus 53-57 18467694-7 2008 These results suggest that bleomycin induces fibrosis by enhancing hyaluronan production, which activates B cells to produce fibrogenic cytokines mainly via TLR4 and induce autoantibody production, and that CD19 deficiency suppresses fibrosis and autoantibody production by inhibiting TLR4 signals. Bleomycin 27-36 toll-like receptor 4 Mus musculus 285-289 34367191-7 2021 We found that at day 14, which corresponds to the inflammatory-to-fibrotic transition phase after bleomycin injection, TLR4, MD2, and Myd88 were induced, and the transcriptome was differentially enriched for genes in those pathways. Bleomycin 98-107 toll-like receptor 4 Mus musculus 119-123 35178456-6 2022 Histopathological changes, inflammatory factors (IL-6, IL-1beta, and TNF-alpha), and the proteins of the TLR4/MyD88/NF-kappaB pathway in bleomycin- (BLM-) induced mice model were examined by hematoxylin-eosin (H&E), Masson or immunohistochemistry staining, Western blot, and enzyme-linked immunosorbent assay analysis. Bleomycin 137-146 toll-like receptor 4 Mus musculus 105-109